
ABSTRACT Purpose: Among the four subtypes of endometrial carcinomas, copy number high/p53-abnormal, especially serous carcinoma, is the most aggressive. Recent studies indicate a possibility of targeted therapy in human epidermal growth factor receptor 2 (HER2)-overexpressing serous carcinomas. This retrospective cross-sectional observational study aimed to evaluate HER2 expression in 125 serous carcinomas. Material and Methods: Clinicopathological features of 125 serous endometrial carcinomas (mostly p53abnormal + p16INK4a block-like staining), including mixed endometrial carcinomas with a distinct serous component, from January 2018 to March 2024 (75 months), were evaluated. HER2 immunoexpression was scored from 0 to 3+. Equivocal tumors (21, 16.8%) were subjected to fluorescence in situ hybridization (FISH) testing. Clinical outcomes, in the form of progression-free survival (PFS) and overall survival (OS), were evaluated in 105 (84%) patients. Results: The age of the patients ranged from 29 to 82 years (median = 63). Among 116 serous endometrial carcinomas and 9 mixed carcinomas, 21 tumors displayed score 3+ (intense, complete, or basolateral/lateral membrane staining in >30% tumor cells); 21 displayed 2+ (intense complete or basolateral/lateral membrane staining in ≤30%, or weak to moderate in ≥10% tumor cells); 28 displayed 1+ (faint incomplete membrane staining in any proportion or weak complete in <10% tumor cells) and 55 showed negative immunostaining. FISH for HER2 amplification in tumors with a 2+ score revealed amplification in 4 tumors. Finally, 25/125 (20%) tumors were HER2-positive. The median PFS was 25.626 months. There was no significant difference in the survival outcomes between HER2-positive and HER2-negative tumors, in terms of PFS ( P = 0.16) or OS ( P = 0.97). However, HER2 overexpression was significantly associated with cervical involvement ( P = 0.061). Conclusions: This constitutes the first comprehensive study on HER2 expression in serous carcinomas from the Indian subcontinent. A notable 20% of HER2-positive serous carcinomas in our study underscores the importance of routine HER2 testing in endometrial carcinomas, particularly in the p53-abnormal subtypes, especially serous carcinomas. This approach could aid in identifying patients who may benefit from targeted therapies in select clinical scenarios.
ABSTRACT Aim: To evaluate the characteristic of the dose, fall inside and outside the stereotactic radiotherapy in theoretical 4π and clinical limiting 2π geometry. This will allow dose escalation to the target volume, without affecting dose falloff to the organs at risk. A total of 50 patients were evaluated in this study. Materials and Methods: Theoretical and clinical models were used to evaluate the dose falloff characteristics. In the theoretical model, targets with diameters of 0.5 cm, 1 cm, 2 cm, and 3 cm were placed inside a 10 cm diameter body/external contour. Dose escalation was 120%, 150%, and 200% at the core. Dose falloff characteristics for the “external contour” were determined. In the clinical model, 30 SRS patients were planned for uniform, 120%, 150%, and 200% doses to the core. Dose falloff at the external contour and variation in OAR doses were evaluated. Results: In the theoretical model, the maximum escalated dose was 181.6%. The characteristic dose falloff was a parabolic function, and there was little change in the spillage dose. Average spillage dose for 0.5 cm, 1 cm, 2 cm, and 3 cm targets was 0.4 ± 0.5%, 1.3 ± 1.9%, 1.5 ± 2.0%, and 0.8 ± 0.8%, respectively. Statistical comparison between uniform and escalated plans was performed using paired t-tests and Cohen’s d effect size. For the clinical model, the maximum dose was 213.9%. Maximum dose differences Δ (120%—uniform), Δ (150%—uniform), and Δ (200%—uniform) for the brainstem were 1.3 ± 3%, 2.5 ± 5%, and 5.4 ± 13%. For the chiasm 0.4 ± 0.9%, 0.3 ± 0.9%, and 0.3 ± 1.0%. Left and right optic nerve, they were 0.3 ± 0.6%, 0.2 ± 0.4%, 0.7 ± 0.7%, and 0.0 ± 0.8%, –0.2 ± 1.8%, and –0.1 ± 1.4%. Conclusion: Dose at the center of the target can be increased, creating a heterogeneous dose distribution without affecting the OAR and spillage doses until target dose coverage remains constant. This property of dose distribution may be helpful in dose escalation for the resistant hypoxic targets. The study also suggests relevance to EUD/TCP modeling for hypoxic tumor escalation in SRS/SRT.
ABSTRACT Purpose: To describe the epidemiological profile, risk factor distribution, anatomical subsite patterns, gender differences, and treatment modalities of head and neck cancer (HNC) patients registered at our hospital. Materials and Methods: This is a retrospective, descriptive, cross-sectional, hospital-based study of histopathologically confirmed HNC patients, registered between January 2020 and June 2025. Data on demographics, personal habits, primary tumor subsite, and treatment received were extracted from medical records. Associations between gender and other categorical variables were assessed using the Chi-square test (significance threshold: P < 0.05). Results: Males accounted for the majority of the cases (72.7%) with peak incidence in the 41–50 and 51-60-year age groups (26.9% each). Oral cavity cancer was the most common diagnosis ( n = 961, 66.88%), followed by hypopharyngeal ( n = 205, 14.27%) and laryngeal carcinoma ( n = 108, 7.52%). Any personal habit was reported by 68.4% of males and 46.8% of females; tobacco smoking and alcohol predominated among men, while reverse smoking and pan chewing were the leading habits among women. Hypopharyngeal carcinoma was disproportionately frequent in females (29.01% vs. 8.72% in males). Conclusions: This study documents a substantial male-predominant burden of HNC strongly associated with modifiable lifestyle risk factors. The distinctive pattern of hypopharyngeal carcinoma in females and pronounced geographical clustering highlight the need for region- and gender-specific early detection and prevention programs.
ABSTRACT Background: Small-cell lung cancer is a relatively homogeneous disease with a worse prognosis. Unlike non-small-cell lung carcinoma, targeted or personalized therapies are not available, which has led to the molecular stratification of small-cell lung carcinoma based on mRNA expression of Achaete-scute homolog 1 (ASCL1), neurogenic differentiation factor 1 (NEUROD1), yes-associated protein (YAP1), and POU Class 2 homeobox 3 (POU2F3), in the hope of gaining some insight into the molecular heterogeneity, and to explore therapeutic vulnerabilities. However, there is scant literature regarding the expression of these markers at protein level/immunohistochemistry and their prognostic and therapeutic relevance. Methods: Formalin-fixed paraffin-embedded tissue samples of 120 consecutively diagnosed unresectable small-cell lung cancer patients during 2016–2022 were classified molecularly based on the immunoexpression of ASCL1, NEUROD1, POU2F3, and YAP1. The subtypes were correlated with insulinoma ssociated protein 1 (INSM1) expression and the response after six cycles of platinum-based chemotherapy. Results: The expression of ASCL1, NEUROD1, POU2F3, and YAP1 was seen in 63.3%, 30%, 7.5%, and 6.5% of cases, respectively. The cases were categorized as ASCL1 dominant (58.5%), NEUROD1 dominant (12.1%), POU2F3+/ASCL1-/NEUROD1-(7.8%), and ASCL1-/NEUROD1-NOS type (21.6%) based on the relative expression of these immunohistochemistry (IHC) markers. All nine POU2F3 positive cases were associated with absent or reduced INSM1 expression. NEUROD1-dominant and POU2F3+/ASCL1-/NEUROD1-subtypes were significantly associated with a poor response to chemotherapy ( P value: 0.027). Conclusion: This is the first study from South-Asian tertiary cancer care center for molecular classification of small-cell lung cancer based on IHC markers. NEUROD1 and POU2F3-dominant subtypes were mostly non-responders to chemotherapy. YAP1 expression was associated with poor overall survival. POU2F3 expression was associated with downregulation of neuroendocrine markers (INSM1 expression).